# CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia

> **NCT07652905** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 24 (estimated)

## Conditions studied

- Plasma Cell Leukemia (PCL)

## Interventions

- **DRUG:** CM336
- **DRUG:** Isatuximab
- **DRUG:** Bortezomib
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT07652905
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-15
- **Primary completion:** 2029-06-30
- **Final completion:** 2031-12-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07652905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07652905, "CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07652905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*